The pharmacists' group points people to its SafeMedication site for a patient-friendly explainer on retatrutide and why unofficial sources are risky.
Recap by typeshit. Post by @ASHPOfficial on X.
He describes a case where a product sourced from neither Eli Lilly nor a compounding pharmacy was followed by liver failure within six days.
The pharmacists' group says the drug looks promising but urges patients to understand what they risk with unofficial sources, and points to its SafeMedication site.
He says the woman's retatrutide came from neither Lilly nor a compounding pharmacy, and her liver failed within six days of starting it.
22:55
Dr. Aleksandra Brown breaks down the buzz around copper peptides and how topical serums compare with injected GHK-Cu.
Volume rose 53% while prices dropped, a sign cheaper access is pulling in patients. Breakdown covers LillyDirect pricing, the $50 Medicare Bridge and Novo's 2027 cuts.
6:25
Dr Almerie compares Lilly's experimental retatrutide with Mounjaro and talks through the case for switching versus holding off until it's approved.
Loading…